Drug Trial Radar · NCT05090891
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
May 5, 2022
Primary completion
Jul 30, 2027
Study completion Jan 20, 2033
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Oct 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
Conditions
- Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
INCB000928Drug
INCBG000928 will be administered QD orally.
PlaceboDrug
Placebo will be administered QD orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind Period: Occurrence of new heterotopic ossification (HO) lesions from baselineTime frame: Week 24
Locations
24 sites in 17 countries. Site status is shown where the registry gives one.
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Penn Medicine - Perelman Center For Advanced Medicine
Philadelphia, Pennsylvania · Active not recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina · Active not recruiting
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Completed
Murdoch Children'S Research Institute
Parkville, Victoria, Australia · Active not recruiting
Albert Einstein Israelite Hospital
São Paulo, Brazil · Active not recruiting
University Health Network Toronto General Hospital
Toronto, Ontario, Canada · Active not recruiting
Centro de Estudios Reumatologicos
Santiago, Chile · Active not recruiting
Beijing Childrens Hospital Capital Medical University
Beijing, China · Recruiting
Tongji Hospital of Tongji University
Shanghai, China · Recruiting
Shanghai Childrens Medical Center
Shanghai, China · Recruiting
Childrens Hospital of Fudan University
Shanghai, China · Recruiting
Ap-Hp Hopital Lariboisiere
Paris, France · Recruiting
Hopital Necker-Enfants Malades
Paris, France · Recruiting
Uniklinik Koln
Cologne, Germany · Recruiting
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
Rome, Italy · Active not recruiting
Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra
Tlalpan, Mexico · Active not recruiting
Amsterdam Umc - Vu Medisch Centrum (Vumc)
Amsterdam, Netherlands · Recruiting
Starship Childrens Hospital
Auckland, New Zealand · Active not recruiting
Groote Schuur Hospital Radiation Oncology
Cape Town, South Africa · Active not recruiting
Seoul National University Hospital
Seoul, South Korea · Active not recruiting
Hospital Universitario Ramon Y Cajal
Madrid, Spain · Recruiting
Royal National Orthopaedic Hospital
Stanmore, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.